20
Participants
Start Date
June 1, 2023
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2026
TCR-T
"Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment."
The Fifth Medical Center of PLA General Hospital, Beijing
Beijing 302 Hospital
OTHER